drugset / Trial / NCT05957380

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

NCT05957380

Phase 4 Completed 120 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a multi-center, double-blind, active-controlled, randomized, parallel clinical study to evaluate the efficacy and safety of DA-2803 in chronic hepatitis B subjects

Timeline

Start
2023-03-20
Primary completion
2024-09-30
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-2803 Unknown Oral
Subject DA-2803-R Unknown Oral